A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,707

Participants

Timeline

Start Date

October 1, 2010

Primary Completion Date

January 25, 2011

Study Completion Date

June 24, 2011

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent seasonal influenza vaccine GSK2282512A

Single intramuscular dose

BIOLOGICAL

FluLavalTM-VB

Single intramuscular dose

BIOLOGICAL

FluLavalTM-YB

Single intramuscular dose

Trial Locations (12)

3400

GSK Investigational Site, Durango

13760

GSK Investigational Site, Endwell

15025

GSK Investigational Site, Jefferson Hills

21075

GSK Investigational Site, Elkridge

55075

GSK Investigational Site, Estado de México

67207

GSK Investigational Site, Wichita

85213

GSK Investigational Site, Mesa

98801

GSK Investigational Site, Wenatchee

V3K 3P4

GSK Investigational Site, Coquitlam

V3R 8P8

GSK Investigational Site, Surrey

G1V 4M6

GSK Investigational Site, Québec

Unknown

GSK Investigational Site, Cuernavaca

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY